Supplementary Table from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

Murakami, Shohei; Barroca, Vilma; Perié, Leïla; Bravard, Anne; Bernardino-Sgherri, Jacqueline; Tisserand, Amandine; Devanand, Caroline; Edmond, Valérie; Magniez, Aurélie; Tenreira Bento, Sabrina; Torres, Claire; Pasquier, Florence; Plo, Isabelle; Vainchenker, William; Villeval, Jean-Luc; Roméo, Paul-Henri; Lewandowski, Daniel

doi:10.1158/2643-3230.22545540.v2

bcd-21-0039_supplementary_table_1_suppt1.pdf (54.43 kB)

Supplementary Table from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

Version 2 2024-01-08, 08:20

Version 1 2023-04-04, 01:44

journal contribution

posted on 2024-01-08, 08:20 authored by Shohei Murakami, Vilma Barroca, Leïla Perié, Anne Bravard, Jacqueline Bernardino-Sgherri, Amandine Tisserand, Caroline Devanand, Valérie Edmond, Aurélie Magniez, Sabrina Tenreira Bento, Claire Torres, Florence Pasquier, Isabelle Plo, William Vainchenker, Jean-Luc Villeval, Paul-Henri Roméo, Daniel Lewandowski

Supplementary Table from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

History

ARTICLE ABSTRACT

Current murine models of myeloproliferative neoplasms (MPNs) cannot examine how MPNs progress from a single bone marrow source to the entire hematopoietic system. Thus, using transplantation of knock-in JAK2V617F hematopoietic cells into a single irradiated leg, we show development of polycythemia vera (PV) from a single anatomic site in immunocompetent mice. Barcode experiments reveal that grafted JAK2V617F stem/progenitor cells migrate from the irradiated leg to nonirradiated organs such as the contralateral leg and spleen, which is strictly required for development of PV. Mutant cells colonizing the nonirradiated leg efficiently induce PV in nonconditioned recipient mice and contain JAK2V617F hematopoietic stem/progenitor cells that express high levels of carbonic anhydrase 1 (CA1), a peculiar feature also found in CD34+ cells from patients with PV. Finally, genetic and pharmacologic inhibition of CA1 efficiently suppresses PV development and progression in mice and decreases PV patients’ erythroid progenitors, strengthening CA1 as a potent therapeutic target for PV. Follow-up of hematopoietic malignancies from their initiating anatomic site is crucial for understanding their development and discovering new therapeutic avenues. We developed such an approach, used it to characterize PV progression, and identified CA1 as a promising therapeutic target of PV.This article is highlighted in the In This Issue feature, p. 265